News/ UK & Europe Boehringer collaborates with Autifony on schizophrenia drug Richard Staines Autifony, Boehringer Ingelheim, European biotech, R&D, schizophrenia, UK biotech 0 Comment Deal could be worth 627.5 million euros Share X Boehringer collaborates with Autifony on schizophrenia drug https://pharmaphorum.com/news/boehringer-collaborates-autifony-schizophrenia-drug/